BTK Degraders in CLL and Lymphoma

I think using the T cell here is important outside of just the other monoclonal antibodies that we use. We're going to have potential new approvals this year with more by specifics coming into the space in DLBCL and follicle lymphoma. BTK degraders are out there as well. They degrade the BTK protein and showed some very pre-limbed data with about a 40% response rate in heavily pre-treated patients. But I do think there will be some relevance for these immunotherapeutic approaches into the future.